ExodusPoint Capital Management’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-11,805
Closed -$378K 1576
2024
Q3
$378K Buy
+11,805
New +$655K ﹤0.01% 1288
2024
Q2
Sell
-1,005
Closed -$146K 1569
2024
Q1
$146K Buy
+1,005
New +$84.9K ﹤0.01% 1393
2022
Q4
Sell
-12,878
Closed -$1.21M 1683
2022
Q3
$1.21M Buy
12,878
+11,190
+663% +$1.59M 0.02% 1029
2022
Q2
$377K Buy
+1,688
New +$565K ﹤0.01% 1448
2022
Q1
Sell
-621
Closed -$411K 2231
2021
Q4
$411K Buy
+621
New +$475K ﹤0.01% 1519
2021
Q3
Sell
-378
Closed -$480K 2163
2021
Q2
$480K Buy
+378
New +$427K 0.01% 1467
2020
Q2
Sell
-1,966
Closed -$687K 1791
2020
Q1
$687K Buy
+1,966
New +$1.39M 0.04% 391
2019
Q2
Sell
-1,119
Closed -$185K 1121
2019
Q1
$185K Buy
+1,119
New +$182K 0.01% 573

Other funds holding CDLX

ExodusPoint Capital Management's CDLX Position: Q4 2024 in Review

ExodusPoint Capital Management sold out of Cardlytics (CDLX) in Q4 2024, closing a stake of 11,805 shares — an estimated $378K sold.

ExodusPoint Capital Management first reported a position in CDLX in Q1 2019 and held it in 8 quarters. The position peaked at $1.21M in Q3 2022. 108 funds tracked by Wall St. Rank hold CDLX as of Q4 2024.

  • ExodusPoint Capital Management reported no remaining Cardlytics position as of Q4 2024 after selling out during the quarter.
  • ExodusPoint Capital Management sold 11,805 Cardlytics shares in Q4 2024, an estimated $378K.
  • ExodusPoint Capital Management first reported a position in Cardlytics in Q1 2019 and held it in 8 quarters.
  • ExodusPoint Capital Management's Cardlytics position peaked at $1.21M in Q3 2022.
  • 108 funds tracked by Wall St. Rank held Cardlytics as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.